Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...

Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...

Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...

Aug. 13, 2002 -- A study of vascular endothelial growth factor (VEGF) reported in the Aug. 15 issue of Cancer may help explain the biological basis for the link between social support and cancer ...

Cancer drug dealmaking is heating up around promising candidates with the potential to top Merck by going after two targets versus the one addressed by the pharmaceutical giant’s blockbuster ...

A closely watched Summit Therapeutics lung cancer drug showed trending improvement on a pivotal study’s measure of how long patients treated with the therapy lived, but the result in the final ...

Predictive value of PIK3CA mutations for response to CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer: A systematic review and meta-analysis. This is an ASCO ...

The literature presented in this review does not indicate a clinically relevant relationship between genetic variations in the VEGF system and the risk of CRC. Hence, these markers will probably not ...

Summit Therapeutics Inc.’s presentation for bispecific antibody ivonescimab in non-small-cell lung cancer could draw some extra attention at next month’s World Conference on Lung Cancer meeting thanks ...